Blog
RSS FeedPosted by Michael Wonder on 30 May 2023
Roche Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Vabysmo (faricimab injection) for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular oedema
29 May 2023 - Roche Canada today announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for ...
Posted by Michael Wonder on 25 May 2023
Australians battling with prostate cancer to benefit from new PBS listing
25 May 2023 - Australians battling prostate cancer that has spread past the prostate will soon benefit from subsidised medicine ...
Posted by Michael Wonder on 25 May 2023
FORUS Therapeutics and the Pan-Canadian Pharmaceutical Alliance complete negotiations for Xpovio (selinexor)
24 May 2023 - The pCPA agreement will support the public listings and reimbursement of Xpovio. ...
Posted by Michael Wonder on 24 May 2023
New life changing treatment for dwarfism added to PBS
24 May 2023 - Children born with the most common form of dwarfism will have access to a new life ...
Posted by Michael Wonder on 23 May 2023
Biden-Harris Administration announces proposal to advance prescription drug transparency in Medicaid
23 May 2023 - New HHS proposal would shed light on cost of prescription drugs and save states and federal ...
Posted by Michael Wonder on 20 May 2023
SMA patients protest inconsistent reimbursement standards for Spinraza
19 May 2023 - Spinal muscular atrophy patients taking Spinraza (nusinersen sodium) are protesting against the Health Insurance Review and ...
Posted by Michael Wonder on 17 May 2023
Astellas seeks to expand reimbursement for prostate cancer drug Xtandi
16 May 2023 - Astellas Pharma has set about to rectify the reimbursement track for Xtandi (enzalutamide), its prostate cancer ...
Posted by Michael Wonder on 16 May 2023
RACGP welcomes asthma puffer decision saving Aussie families time and money
15 May 2023 - The Royal Australian College of GPs (RACGP) has welcomed the PBAC's decision to remove limitations requiring ...
Posted by Michael Wonder on 15 May 2023
Alzheimer’s treatment Leqembi could cost Medicare up to $5 billion per year, study estimates
12 May 2023 - The study authors said the estimated costs to the program for seniors are conservative and spending ...
Posted by Michael Wonder on 12 May 2023
PBAC backs ongoing access to low-dose asthma puffer for Aussie kids
12 May 2023 - The independent, expert group advising the Australian Government on PBS medications has reviewed its recommendation to put ...
Posted by Michael Wonder on 11 May 2023
Ovarian cancer: Bay of Plenty mother spends more than $130,000 on treatments
12 May 2023 - Four cancer treatments in three years: $132,775. ...
Posted by Michael Wonder on 10 May 2023
Reforming opioid dependence treatment access
10 May 2023 - In the 2023-24 Budget, the Australian Government committed $377.3 million over 4 years from 2023–24 (and $98.4 ...
Posted by Michael Wonder on 05 May 2023
Patients lose access to free medicines amid spat between drugmakers, health plans
2 May 2023 - Pharmaceutical companies have cut financial assistance to thwart health plan tactics. ...
Posted by Michael Wonder on 04 May 2023
Access to cancer medicines in the UK
1 May 2023 - On 31 January 2020, the UK formally ended it's 47 year membership of the EU. As a ...
Posted by Michael Wonder on 04 May 2023
Gene therapies are still hampered by substantial delays between approval and launch
3 May 2023 - Gene therapies hold promise for treating a wide range of diseases. Innovative companies such as bluebird bio ...